Vera Therapeutics Q2 loss widens less than expected

Vera Therapeutics

10/08/2026 22:07

Overview
US biotech's Q2 EPS widened less than analyst expectations
Company launched TRUTAKNA, first FDA-approved BAFF and APRIL inhibitor for IgA nephropathy
Company announced executive transition with new Chief Regulatory Officer

Outlook
Company expects final efficacy analysis from ORIGIN 3 trial in Q3 2026
Anticipated sBLA submission to FDA expected in Q4 2026
Potential full approval of TRUTAKNA in IgAN expected in 2027

Result Drivers
TRUTAKNA LAUNCH - Co cited the accelerated FDA approval and commercial launch of TRUTAKNA for IgA nephropathy as a key milestone
CLINICAL PROFILE - Co highlighted TRUTAKNA's Phase 3 trial results showing reduction in proteinuria and favorable safety profile
COMMERCIAL EXECUTION - Co pointed to experienced team and early encouraging reception for TRUTAKNA in the U.S. market

Company press release: ID:nGNX6KGCtR

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Beat
$-1.52
-$1.56 (11 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vera Therapeutics, Inc. is $78.00, about 137.2% above its August 7 closing price of $32.89

Reuters Recommended Reads
Aug 10 - Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)